Abstract
One of the main barriers to more efficacious use of modern chemotherapeutic agents, is the collateral toxicity exhibited in normal, highly proliferative tissues, primarily the haemopoietic, gastrointestinal and Pulmonary tissues. Drug resistance of tumours to these drugs compounds this problem. This review discusses the role of O6-alkylguanine-DNA alkyltransferase (ATase) in conferring protection against O6-alkylating agents in normal tissue, focusing mainly on the haemopoietic compartment. The development of mutant forms of ATase, which are resistant to the effects of soluble analogues of O6-alkylation such as O6-benzylguanine, is examined and the gene therapy approach of combining these two strategies to confer chemoprotection to vulnerable tissues whilst sensitising malignant tissue is reviewed.
Keywords: Genetic Chemoprotection, Alkylguanine-DNA-Alkyltrans-ferases, haemopoietic compartment, collateral toxicity, cytosine arabinoside
Current Gene Therapy
Title: Genetic Chemoprotection with Mutant O6-Alkylguanine-DNA-Alkyltransferases
Volume: 2 Issue: 1
Author(s): D. A. Hobin and L. J. Fairbairn
Affiliation:
Keywords: Genetic Chemoprotection, Alkylguanine-DNA-Alkyltrans-ferases, haemopoietic compartment, collateral toxicity, cytosine arabinoside
Abstract: One of the main barriers to more efficacious use of modern chemotherapeutic agents, is the collateral toxicity exhibited in normal, highly proliferative tissues, primarily the haemopoietic, gastrointestinal and Pulmonary tissues. Drug resistance of tumours to these drugs compounds this problem. This review discusses the role of O6-alkylguanine-DNA alkyltransferase (ATase) in conferring protection against O6-alkylating agents in normal tissue, focusing mainly on the haemopoietic compartment. The development of mutant forms of ATase, which are resistant to the effects of soluble analogues of O6-alkylation such as O6-benzylguanine, is examined and the gene therapy approach of combining these two strategies to confer chemoprotection to vulnerable tissues whilst sensitising malignant tissue is reviewed.
Export Options
About this article
Cite this article as:
Hobin A. D. and Fairbairn J. L., Genetic Chemoprotection with Mutant O6-Alkylguanine-DNA-Alkyltransferases, Current Gene Therapy 2002; 2 (1) . https://dx.doi.org/10.2174/1566523023348255
DOI https://dx.doi.org/10.2174/1566523023348255 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Structure Based Lead Optimization Approach in Discovery of Selective DPP4 Inhibitors
Mini-Reviews in Medicinal Chemistry Specific Targeting of Akt Kinase Isoforms: Taking the Precise Path for Prevention and Treatment of Cancer
Current Drug Targets Melittin: A Natural Peptide with Expanded Therapeutic Applications
The Natural Products Journal Nitric Oxide is a Key Molecule Serving as a Bridge between Radiation-Induced Bystander and Adaptive Responses
Current Molecular Pharmacology Anticancer Active Heterocyclic Chalcones: Recent Developments
Anti-Cancer Agents in Medicinal Chemistry Mechanisms of Immune Modulation by Mesenchymal Stromal Cells and Clinical Translation
Current Molecular Medicine Expression, Distribution and Regulation of Phosphodiesterase 5
Current Pharmaceutical Design Drug Delivery Across the Blood-Brain Barrier
Current Drug Delivery Glucose Oncometabolism of Esophageal Cancer
Anti-Cancer Agents in Medicinal Chemistry Nanofibers: New Insights for Drug Delivery and Tissue Engineering
Current Topics in Medicinal Chemistry Anti-Angiogenic Therapies for Children with Cancer
Current Cancer Drug Targets The Role of CXC-Chemokine IL-8, IL-6 and CXCR2 Receptor in Lymphoplasmacytic Lymphoma: Correlations with Microvascular Characteristics and Clinical Features
Current Angiogenesis (Discontinued) New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets Hypoxia Helps Glioma to Fight Therapy
Current Cancer Drug Targets Immuno-Isolation in Cancer Gene Therapy
Current Gene Therapy B7-H3 Immune Checkpoint Protein in Human Cancer
Current Medicinal Chemistry 3D-QSAR and Docking Studies of 4-morpholinopyrrolopyrimidine Derivatives as Potent mTOR Inhibitors
Letters in Drug Design & Discovery Innovative Cancer Treatments that Augment Radiotherapy or Chemotherapy by the Use of Immunotherapy or Gene Therapy
Recent Patents on Anti-Cancer Drug Discovery Targeting Histone Deacetylases in Neuroblastoma
Current Pharmaceutical Design The Potential Role of Peritumoral Apparent Diffusion Coefficient Evaluation in Differentiating Glioblastoma and Solitary Metastatic Lesions of the Brain
Current Medical Imaging